ARv7 represses tumor suppressors genes in castration-resistant prostate cancer
收藏NIAID Data Ecosystem2026-03-12 收录
官方服务：
资源简介：
This SuperSeries is composed of the SubSeries listed below. Refer to individual Series
应用场景：
创建时间：
2021-09-05
相关数据集
Systematic characterization of epigenetic modifying enzymes identifies KDM3B as a key regulator in castration resistant prostate cancer. Systematic characterization of epigenetic modifying enzymes identifies KDM3B as a key regulator in castration resistant prostate cancer
Androgen deprivation therapy (ADT) is the standard care for prostate cancer patients who fail surgery and radiotherapy. While initially effective, the cancer almost always recurs into a more aggressiv
NIAID Data Ecosystem100
Phenotypic characterization of two novel cell line models of castration resistant prostate cancer
Purpose: Resistance to androgen deprivation therapies is a major driver of mortality in advanced prostate cancer. Therefore, there is a need to develop new pre-clinical models that allow the investiga
NIAID Data Ecosystem50
Human prostate cancer cells (VCaP and AIVCaP): siAR alone (single siRNA) vs. siAR plus OPRK1 (combo-siRNA)
Through comparative genomics using PDX models of androgen-dependent (AD) and castration-resistant (CR) tumors, we identify opioid receptor kappa 1 (OPRK1) as being associated with castration-resistanc
NIAID Data Ecosystem30
Integrated single-cell analysis defines the epigenetic basis of castration-resistant prostate luminal cells
Understanding prostate response to castration and androgen receptor signaling inhibitors (ARSI) is critical to improving long-term prostate cancer (PCa) patient survival. We use a multi-omics approach
NIAID Data Ecosystem100
ARv7 represses tumor suppressors genes in castration-resistant prostate cancer [RNA-Seq]
Endocrine therapies in prostate cancer (PCa) treatment block androgen receptor (AR) function, but are palliative as tumors progress to a lethal, castration-resistant state (CRPC). CRPC remains depende
NIAID Data Ecosystem50
